Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

---

Bastidas A., de la Serna J., El Idrissi M., Oostvogels L., Quittet P., Lopez-Jimenez J., ...More

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol.322, no.2, pp.123-133, 2019 (SCI-Expanded, Scopus)

• Publication Type: Article / Article
• Volume: 322 Issue: 2
• Publication Date: 2019
• Doi Number: 10.1001/jama.2019.9053
• Journal Name: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.123-133
• Open Archive Collection: AVESIS Open Access Collection
• Hacettepe University Affiliated: Yes

Abstract

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.